Related Experiment Videos
Recurrent injection site reactions from interferon beta 1-b.
Lena Samuel1, Eve J Lowenstein
1SUNY Health Science Center Department of Dermatology, Brooklyn, NY 11203, USA.
Journal of Drugs in Dermatology : JDD
|May 6, 2006
Summary
Recombinant human interferon beta-1b can cause common skin reactions, particularly in females with multiple sclerosis (MS). Dermatologists should recognize these injection site reactions may not require stopping this important immune-modulatory therapy.
Area of Science:
- Immunology
- Dermatology
- Neurology
Background:
- Recombinant human interferon beta-1b is a key immune-modulatory therapy for multiple sclerosis (MS).
- Injectable interferon therapies are associated with cutaneous side effects, including injection site reactions.
- Injection site reactions are reported more frequently in female patients.
Observation:
- This report details a case of prolonged susceptibility to injection site reactions.
- The patient experienced these reactions over a decade of continuous interferon beta-1b treatment for MS.
- The reactions were characterized by injection site issues.
Findings:
- Skin reactions, such as injection site reactions, are common with interferon beta-1b therapy.
- Female patients appear more prone to developing injection site reactions.
- Prolonged susceptibility to these reactions can occur, even with long-term use.
Implications:
- Dermatologists must be aware of the high prevalence of skin reactions to interferon beta-1b.
- Recognition of these reactions is crucial for patient management.
- These common reactions often do not warrant discontinuation of essential MS therapy.